Haemonetics Corporation (HAE)vsMerck & Company Inc (MRK)
HAE
Haemonetics Corporation
$52.67
-5.30%
HEALTHCARE · Cap: $2.75B
MRK
Merck & Company Inc
$113.56
+0.36%
HEALTHCARE · Cap: $277.02B
Smart Verdict
WallStSmart Research — data-driven comparison
Merck & Company Inc generates 4889% more annual revenue ($65.77B vs $1.32B). MRK leads profitability with a 13.6% profit margin vs 13.3%. HAE appears more attractively valued with a PEG of 0.91. HAE earns a higher WallStSmart Score of 64/100 (C+).
HAE
Buy64
out of 100
Grade: C+
MRK
Buy53
out of 100
Grade: C-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+44.1%
Fair Value
$102.84
Current Price
$52.67
$50.17 discount
Margin of Safety
-15.7%
Fair Value
$97.76
Current Price
$113.56
$15.80 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Growing faster than its price suggests
Attractively priced relative to earnings
Reasonable price relative to book value
Strong operational efficiency at 21.0%
Earnings expanding 28.4% YoY
Mega-cap, among the largest globally
Every $100 of equity generates 37 in profit
Strong operational efficiency at 38.1%
Generating 2.9B in free cash flow
Areas to Watch
Distress zone — elevated risk
Elevated debt levels
Revenue declined 2.7%
Premium valuation, high expectations priced in
4.9% revenue growth
Weak financial health signals
Expensive relative to growth rate
Comparative Analysis Report
WallStSmart ResearchBull Case : HAE
The strongest argument for HAE centers on PEG Ratio, P/E Ratio, Price/Book. PEG of 0.91 suggests the stock is reasonably priced for its growth.
Bull Case : MRK
The strongest argument for MRK centers on Market Cap, Return on Equity, Operating Margin.
Bear Case : HAE
The primary concerns for HAE are Altman Z-Score, Debt/Equity, Revenue Growth.
Bear Case : MRK
The primary concerns for MRK are P/E Ratio, Revenue Growth, Piotroski F-Score.
Key Dynamics to Monitor
HAE profiles as a declining stock while MRK is a value play — different risk/reward profiles.
HAE carries more volatility with a beta of 0.36 — expect wider price swings.
MRK is growing revenue faster at 4.9% — sustainability is the question.
MRK generates stronger free cash flow (2.9B), providing more financial flexibility.
Bottom Line
HAE scores higher overall (64/100 vs 53/100). Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Haemonetics Corporation
HEALTHCARE · MEDICAL DEVICES · USA
Haemonetics Corporation, a healthcare company, offers medical products and solutions. The company is headquartered in Boston, Massachusetts.
Visit Website →Merck & Company Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.
Visit Website →Compare with Other MEDICAL DEVICES Stocks
Want to dig deeper into these stocks?